Hospital Systems for the Detection and Prevention of Adverse Drug Events

被引:10
|
作者
Cheng, C. M. [1 ]
机构
[1] Univ Calif San Francisco, Medicat Outcomes Ctr, Dept Clin Pharm, San Francisco, CA 94143 USA
关键词
D O I
10.1038/clpt.2010.356
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In its 2006 report "Preventing Medication Errors," the Institute of Medicine (IOM) estimated that more than 1.5 million preventable adverse drug events (ADEs) occur annually in the United States. Many organizations, including the IOM, the Institute for Safe Medication Practices, the US Food and Drug Administration, and the Leap Frog Group for Patient Safety have advocated the implementation of technologies to reduce ADEs, particularly in the hospital setting. Many technologies have emerged in recent years to reduce ADEs at various points in the medication use process; however, interfacing some of these key technologies with existing hospital systems poses significant challenges.
引用
收藏
页码:779 / 781
页数:3
相关论文
共 50 条
  • [1] Toward Automatic Detection and Prevention of Adverse Drug Events
    Leroy, Nicolas
    Chazard, Emmanuel
    Beuscart, Regis
    Beuscart-Zephir, Marie Catherine
    [J]. ADVANCES IN INFORMATION TECHNOLOGY AND COMMUNICATION IN HEALTH, 2009, 143 : 30 - +
  • [2] Patient Safety: Detection and Prevention of Adverse Drug Events
    Beuscart, Regis
    McNair, Peter
    Darmoni, Stefan J.
    Koutkia, Vassilis
    Maglaveras, Nicos
    Beuscart-Zephir, Marie-Catherine
    Nohr, Christian
    [J]. MEDICAL INFORMATICS IN A UNITED AND HEALTHY EUROPE, 2009, 150 : 968 - 971
  • [3] Prevention of adverse drug events
    不详
    [J]. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2001, 8 (04) : 256 - 256
  • [4] Prevention of adverse drug events
    Farmer, B.
    [J]. CLINICAL TOXICOLOGY, 2014, 52 (06) : 573 - 578
  • [5] INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION
    BATES, DW
    CULLEN, DJ
    LAIRD, N
    PETERSEN, LA
    SMALL, SD
    SERVI, D
    LAFFEL, G
    SWEITZER, BJ
    SHEA, BF
    HALLISEY, R
    VANDERVLIET, M
    NEMESKAL, R
    LEAPE, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01): : 29 - 34
  • [6] Data-mining-based detection and prevention of adverse drug events
    Chazard, E.
    Preda, C.
    Merlin, B.
    Ficheur, G.
    Beuscart, R.
    [J]. IRBM, 2009, 30 (04) : 192 - 196
  • [7] A Statistics-based Approach of Contextualization for Adverse Drug Events Detection and Prevention
    Chazard, Emmanuel
    Bernonville, Stephanie
    Ficheur, Gregoire
    Beuscart, Regis
    [J]. QUALITY OF LIFE THROUGH QUALITY OF INFORMATION, 2012, 180 : 766 - 770
  • [8] The PSIP project for Adverse Drug Events prevention
    Bernonville, S.
    Guillot, B.
    Pedersen, H. G.
    Koutkias, V.
    Beuscart, R.
    [J]. IRBM, 2013, 34 (4-5) : 263 - 266
  • [9] Financial impact of adverse drug events prevention
    Plichon, Philippe
    Bousquet, Chloe
    Pourrat, Xavier
    Delerue, Dominique
    Remerand, Francis
    Rosset, Philippe
    Favard, Luc
    Grassin, Jacqueline
    Bourgoin, Helene
    [J]. PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 248 - 249
  • [10] Adverse drug events as a cause of hospital admission
    Lagos, Ximena
    Tripailaf, Gustavo
    Kyonen, Monica
    Castillo, Fabiola
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (04) : 841 - 842